This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Richard D. Moore, MD, MHS; Richard E. Chaisson, MD
The Johns Hopkins University School of Medicine Baltimore, Md

Julia Hidalgo, ScD
Maryland Department of Health and Mental Hygiene Baltimore

JAMA. 1994;272(13):1001.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—In their well-done study of the duration of survival benefit of zidovudine in patients with AIDS, Dr Lundgren and colleagues¹ comment that visual inspection of product-limit plots for our study² suggest a survival benefit of about 1 year's duration. Our observational study reported survival estimates on 352 patients who received zidovudine and 362 patients who did not receive zidovudine who were first diagnosed with AIDS from April 1987 through June 1989 and had longitudinal follow-up through June 1990. A total of 470 patients (66%) died during follow-up. When survival from diagnosis of AIDS was analyzed by a time-dependent Cox regression in a manner similar to Lundgren et al, we derived the results listed in the Table. A second time-dependent Cox regression analysis was also done using the following model: relative hazard (t) = exp(B1+[B2xtime]), where B1 provides an estimate of the relative hazard of use vs . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?